These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 25327907)
1. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient. Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907 [No Abstract] [Full Text] [Related]
2. Is there an association between 5-azacitidine and ototoxicity? Malik A; Misbah S; Spaccavento C; Yudelman I J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015 [No Abstract] [Full Text] [Related]
3. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes. Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068 [No Abstract] [Full Text] [Related]
4. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome. Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928 [No Abstract] [Full Text] [Related]
6. Decitabine. Gore SD; Jones C; Kirkpatrick P Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522 [No Abstract] [Full Text] [Related]
7. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome. Adams CD; Szumita PM; Baroletti SA; Lilly CM Pharmacotherapy; 2005 May; 25(5):765-8. PubMed ID: 15899739 [TBL] [Abstract][Full Text] [Related]
8. Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome. Nair GB; Charles M; Ogden L; Spiegler P Respir Care; 2012 Apr; 57(4):631-3. PubMed ID: 22005027 [TBL] [Abstract][Full Text] [Related]
9. Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment. Feldmann G; Brossart P; von Lilienfeld-Toal M Ann Hematol; 2013 Nov; 92(11):1577-9. PubMed ID: 23584506 [No Abstract] [Full Text] [Related]
10. Interstitial lung disease associated with azacitidine use: a case report. Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671 [TBL] [Abstract][Full Text] [Related]
11. Azacitidine and the beginnings of therapeutic epigenetic modulation. O'Dwyer K; Maslak P Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335 [TBL] [Abstract][Full Text] [Related]
12. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924 [TBL] [Abstract][Full Text] [Related]
13. Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan. Hayashi M; Takayasu H; Tada M; Yamazaki Y; Tateno H; Tazawa S; Wakabayashi A; Iwasaki T; Tsuchiya Y; Yamashita J; Takeda N; Tomita S; Mori H; Kokubu F Intern Med; 2012; 51(17):2411-5. PubMed ID: 22975559 [TBL] [Abstract][Full Text] [Related]